Insulin Lispro

Evidence Level: L5

Predicted Indications: 9

Insulin Lispro

Pharmacist Assessment Report

Insulin Lispro: From Type 2 Diabetes Mellitus to Autoimmune Oophoritis

One-Sentence Summary

Insulin lispro is a rapid-acting insulin analogue originally used to treat type 1 and type 2 diabetes mellitus, including diabetic ketoacidosis. The TxGNN model predicts it may be effective for autoimmune oophoritis, but no clinical trials and no publications currently support this prediction, so it rests on model output alone.

Quick Overview

Item	Content
Original Indication	Type 2 diabetes mellitus (also type 1 diabetes mellitus and diabetic ketoacidosis)
Predicted New Indication	Autoimmune oophoritis
TxGNN Prediction Score	0.9978
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (14 of 14) – CDSCO approval status is not included in this data
Number of Listed Products	14 (valid: 14)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, insulin lispro is a rapid-acting insulin analogue, its efficacy in diabetes mellitus is well established, and mechanistically it acts through insulin signaling.

For autoimmune oophoritis, the only link is speculative. Insulin signaling operates in ovarian granulosa cells, and autoimmune endocrine conditions can overlap with type 1 diabetes. This is not a therapeutic rationale for insulin lispro. The high TxGNN score is a model prediction and should not be read as evidence of benefit.

Other high-ranking predictions show the same pattern. Several (thiamine-responsive dysfunction syndrome, pancreatic agenesis) mainly reflect diabetes management, which is an extension of the existing indication. Several others (stiff person syndrome spectrum) reflect shared anti-GAD autoimmunity with type 1 diabetes. Two (drug-induced localized lipodystrophy, pressure-induced localized lipoatrophy) likely reflect injection-site adverse effects of insulin and are not therapeutic signals. Opsismodysplasia has a pathway-level link through INPPL1 (SHIP2), a negative regulator of insulin signaling, but no evidence that insulin alters the skeletal phenotype.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for autoimmune oophoritis.

For the rank 7 prediction, pancreatic agenesis, one general review is available. It is indirect evidence only:

PMID	Year	Type	Journal	Key Findings
12150359	2002	Review	Journal of the American Pharmaceutical Association	Overview of insulin therapy in type 2 diabetes and practical aspects of starting it; does not address pancreatic agenesis directly

India Market Information

The approved indication text is not recorded for these registrations. Five of the 14 valid registrations are listed below.

Authorization Number	Product Name	Dosage Form	Approved Indication
103754	Humalog 100IU/ml Kwikpen (Eli Lilly and Company India)	Disposable pen of 3 ml solution for injection	Not specified
103700	Humalog 100IU/ml Solution for Injection (Eli Lilly and Company India)	Cartridge of 3 ml solution for injection	Not specified
104016	Humalog 200IU/ml Kwikpen (Eli Lilly and Company India)	Pre-filled pen of 3 ml solution for injection	Not specified
73299	Eglucent Rapid 100IU/ml Kwikpen (Lupin)	Pre-filled pen of 3 ml solution for injection	Not specified
103706	Humalog Mix 25 100IU/ml Cartridge (Eli Lilly and Company India)	Cartridge of 3 ml injection	Not specified

All 14 registrations are currently valid. They are injectable only (cartridges and pens), in solution and premixed suspension forms.

Review correction (2026-11-06): Originally stated: “All 14 registrations are single-ingredient products and currently valid.” Removed: it described the products as single-ingredient or combination products in a way that did not match the Indian medicine data (the Indian Medicine Dataset as of 2026-11-06). Source: Indian Medicine Dataset.

Safety Considerations

Drug Interactions: The data compiled for this report list 352 known interactions. Most of those shown are moderate, with a few minor. Examples:
- Moderate: metformin, alogliptin, albiglutide (additive glucose-lowering effects), epinephrine, salbutamol, formoterol, phenylephrine, pseudoephedrine, hydrocortisone, estradiol, ethinylestradiol, levonorgestrel, hydrochlorothiazide, acetazolamide, doxycycline, acebutolol, alpelisib, ethanol
- Minor: topical hydrocortisone, topical alclometasone

Please refer to the package insert for warnings and contraindications, which were not available in the data compiled for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction for autoimmune oophoritis is supported only by a model score, with no clinical trials or literature, and the mechanistic link is speculative. Many of the other top predictions reflect existing diabetes care or injection-site adverse effects rather than new therapeutic opportunities.

To proceed, the following is needed:

Package insert warnings and contraindications (a blocking gap for safety screening)
Detailed mechanism of action data
Preclinical or clinical evidence linking insulin lispro to autoimmune oophoritis
Assessment of route compatibility and similarity to the original indication

Review Log

Below is the review log for this page: statements checked against official Indian medicine data (the Indian Medicine Dataset used by this site). Corrections are limited to basic factual statements; model predictions, evidence levels, and conclusions were not rewritten.

Review date	Item	Action	Source
2026-11-06	Removed: “single-ingredient products and”	Corrected	Indian Medicine Dataset

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.